2025年11月6日， 健康元 （ 600380 ）药业集团（600380.SH）宣布，其与拜耳合作开发的全球首创PREP抑制剂正式启动IIa期临床试验，首位慢性阻塞性肺疾病（COPD）患者顺利入组。

GSK今天宣布，其“first-in-class”抗体疗法Nucala（mepolizumab），在治疗成人慢性阻塞性肺病（COPD）患者的3期临床试验MATINEE中获得积极结果。这一试验结果将支持GSK与监管机构讨论，以提交申请扩展Nucala的适应症。 该临床试验招募了具有广泛临床表现的COPD患者 ...

-Ritedose is the development partner and manufacturer of Ohtuvayre (ensifentrine)*, the first inhaled product with a novel mechanism of action in more than 20 years for the maintenance treatment of ...

SummaryChronic Obstructive Pulmonary Disease (COPD) is a progressive disorder associated with chronic inflammation of the airways and lungs. Persistent breathing difficulties and repeated ...

CHICO — Enloe Medical Center has launched a new series of classes aimed at educating people living with Chronic Obstructive Pulmonary Disease, commonly known as COPD, which causes breathing-related ...

A new class of drugs for chronic obstructive pulmonary disease improves lung function and reduces the likelihood of exacerbations, but do not improve patients' quality of life, according to a Cochrane ...

Check this table to make sure you can use your COPD inhalers together Medically reviewed by Sanja Jelic, MD Most people with chronic obstructive pulmonary disease (COPD) use an inhaler every day to ...

I was diagnosed with COPD last year after struggling with multiple symptoms. I quit smoking over 10 years ago, but I’m ...

SOUTHAMPTON’S chronic obstructive pulmonary disease (COPD) maintenance class is hosting a jumble sale to raise money for two charities. The event will be held on March 23, from 2pm, at Moorlands ...